Navigation Links
ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Date:9/1/2010

f 164 patients (9.2 percent) receiving fenretinide at either dose developed CNV. While the results were statistically significant (p=0.039), this was the result of exploratory and ad hoc analyses.

Preclinical studies show that fenretinide reduces the expression of vascular endothelial growth factor (VEGF) isoforms. These proteins are known to cause aberrant growth of leaky vessels within the retina and have been implicated in severe vision loss in patients with CNV. Fenretinide was also found to upregulate the expression of complement factor H, a potent inhibitor of the inflammatory pathway. Dysfunction or deficits in complement factor H are known to significantly increase risk for development of CNV. This preclinical data suggests that the anti-angiogenic and anti-inflammatory properties of fenretinide may underlie the reduced incidence of CNV observed in the clinical trial.

The accumulation of retinol (vitamin A)-derived toxins in the eye is believed to be a significant risk factor for the development of GA. The ability of fenretinide to reduce the delivery of retinol to the eye, and therefore reduce accumulation of these toxins, is thought to mitigate this risk. Analysis of GA lesion growth by color fundus photography showed a trend for slowing of lesion growth in patients receiving fenretinide. This trend was particularly evident in patients in the 300 mg dose group who had substantial reductions in serum retinol and its carrier protein, retinol binding protein (RBP). Data from the 300 mg dose group demonstrated a reduction in median lesion growth when RBP and retinol levels were reduced by more than 50 percent. This finding supports the proof of concept that reduction of circulating RBP and retinol reduces lesion growth in patients with GA.

Full analysis of all lesion size measurements is ongoing. The complete data will be presented later this year at the annual meeting of the American Academy of Ophthalmology.

About ReVision The
'/>"/>

SOURCE ReVision Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
2. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
3. Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
4. Cord Blood America Says Debt Reduced $4.194 Million in 2009
5. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
6. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
7. The toxicity of antimicrobial silver in products can be reduced
8. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
9. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
10. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
11. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Six startups from Russia traveled ... as part of the U.S.-Russia Innovation Corridor (USRIC) ... biotechnology startups to participate in the program since ... the University of Maryland (UMD) signed a Memorandum ... universities in the biomedical industry in 2013. , ...
(Date:4/23/2015)... SAN FRANCISCO, Calif. , April 23, 2015  Veracyte, ... has entered into a definitive agreement to sell approximately ... placement. Under the agreement, the investors will purchase an ... purchase price of $8.15 per share, the closing stock ... led by new and existing investors, including Broadfin Capital, ...
(Date:4/23/2015)... 2015  Propanc Health Group Corporation (OTCBB: PPCH) ... the development of cancer treatments for patients with ... includes PRP, a patented formulation consisting of two ... as the enzyme amylase designed to synergistically enhance ... of anti-cancer agents working in combination with pro-enzymes, ...
(Date:4/22/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today reported ... For the first quarter ended March 31, 2015, ... or $0.08 per share, compared to a net loss ... same period in 2014. As of March 31, 2015, ... interest receivable of $226.1 million. Revenues for ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8
... 23 Cordex Pharma, Inc., formerly known as Duska Therapeutics, ... host a scientific briefing on Thursday, January 29, 2009, at ... will be Jonathan S. Stamler, MD, the George Barth Geller ... Medicine and of Biochemistry at Duke University Medical ...
... MENLO PARK, Calif., Jan. 23 XTENT, Inc. (Nasdaq: ... an investment bank to help the company pursue strategic alternatives ... the company,s assets or other types of merger or acquisition ... in the capital markets, we believe it is in the ...
... P2R Associates today announced it,received eight prestigious ... Communication Professionals. The awards were presented,recognizing outstanding ... 5,000 entries from throughout the U.S. and several,foreign ... honored to be recognized for our work," said ...
Cached Biology Technology:Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5XTENT to Retain Investment Bank to Pursue Strategic Alternatives 2XTENT to Retain Investment Bank to Pursue Strategic Alternatives 3P2R Associates Presented with Eight MarCom Awards for Client Strategic Communication Programs 2
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... PROVIDENCE, R.I. [Brown University] In recent years, researchers ... soldiers returning home from battlefields in Afghanistan or Iraq ... have trouble keeping bacteria from entering the body through ... "You need to close (the area) where the bacteria ...
... and storage intensifies as scientists from the Earth Sciences ... examine the capacity for storing carbon dioxide underground, in ... Greenhouse Gases: Science & Technology . The ... earlier study by Ehlig-Economides and Economides1, countering their claims ...
... Bryozoa. Earlier studies were based on visible characteristics of these ... are related to each other. To understand the evolution of ... is necessary to use molecular data, that,s to say DNA," ... University of Gothenburg. When Bryozoa were discovered in the ...
Cached Biology News:Nanomodified surfaces seal leg implants against infection 2Carbon capture and storage: Carbon dioxide pressure dissipates in underground reservoirs 2Unknown animals nearly invisible but yet there 2
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
Biology Products: